Inclusion Criteria:

For inclusion in the trial, all of the following inclusion criteria must be fulfilled:

- Subject has given written informed consents before any trial-related activities are
carried out

- Male or female, ≥18 years of age at the time of informed consent, inpatient or
outpatient

- Diagnosis of histologically or cytologically confirmed NSCLC, stage IIIB NSCLC with
pleural effusion or stage IV

- Presence of at least 1 uni-dimensionally measurable index lesion, whereby index
lesions must not lie in a previously irradiated area

- ECOG performance status of 0 or 1 at inclusion in the trial

- White blood count ≥3 x 10^9/L with neutrophils ≥1.5 x 10^9/L, platelet count ≥100 x
10^9/L, and hemoglobin ≥5.6 mmol/L (9 g/dL)

- Total bilirubin ≤1.5 x upper limit of normal (ULN) range

- Aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) ≤5 x ULN

- Glomerular filtration rate (GFR) ≥60 mL/min. The creatinine clearance estimated by
the Cockroft-Gault formula will be used as a surrogate for the GFR

- Effective contraception i.e., barrier method (condoms, diaphragm), oral, injectable
or implant birth control, for both male and female subjects during the whole trial
period and for at least 6 months after the end of trial treatment, if the risk of
conception exists

- Recovered from relevant toxicities prior to inclusion in the trial

Exclusion Criteria:

Subjects are not eligible for this trial if they fulfill any of the following exclusion
criteria:

- Previous exposure to EGFR-targeting therapy

- Previous chemotherapy for NSCLC; neo-adjuvant or adjuvant (radio-)chemotherapy is
allowed if it was finished 6 months prior to start of trial treatment

- Major surgery within 30 days prior to inclusion in the trial

- Prior chest irradiation within 90 days prior to inclusion in the trial (palliative
radiation of bone lesions is allowed)

- Participation in another clinical trial or treatment with any investigational
agent(s) within 30 days prior to inclusion in the trial

- Concurrent chronic systemic immune therapy, chemotherapy for disease other than
cancer, or hormone therapy for the treatment of cancer not indicated in the trial
protocol

- Documented or symptomatic brain metastasis

- Pre-existing ascites Grade ≥2 and/or pericardial effusion Grade ≥2

- Superior vena cava syndrome contra-indicating hydration

- Previous malignancy in the last 5 years except basal cell carcinoma of the skin or
pre-invasive carcinoma of the cervix

- Active infection (infection requiring intravenous [IV] antibiotics), including active
tuberculosis, known and declared human immunodeficiency virus (HIV)

- Myocardial infarction within 6 months prior to inclusion into the trial, uncontrolled
congestive heart failure; or any current Grade 3 or 4 cardio-vascular disorder
despite treatment

- Known hypersensitivity reaction to any of the components of trial treatments

- Symptomatic peripheral neuropathy National Cancer Institute-Common Toxicity Criteria
(NCI-CTC) Grade ≥2 and/or ototoxicity Grade ≥2, except if due to trauma or mechanical
impairment due to tumor mass

- History of significant neurologic or psychiatric disorders including dementia,
seizures, bipolar disorder

- Medical or psychological condition that would not permit the subject to complete the
trial or sign informed consent

- Legal incapacity or limited legal capacity

- Known drug abuse

- Pregnancy (absence to be confirmed by serum β-HCG test) or lactation period